Loading stock data…
ANGO
$12.34+0.41 (+3.44%)
After Hours$12.34+0.00 (+0.00%)· Last close Jun 9
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AngioDynamics, Inc. in the Healthcare sector is trading at $12.34. Wall Street consensus targets $18.00 (4 analysts), implying a +45.9% move over the next 12 months. The stock is currently 12% below its 52-week high of $13.99, remaining 8.9% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +45.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$12.34
Potential Downside
0%
Whystock Fair Value$12.34
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internation...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-18.11%
Volume
Today's trading volume
225,954
Recent News
Wall Street Analysts See a 50.5% Upside in AngioDynamics (ANGO): Can the Stock Really Move This High?
The mean of analysts' price targets for AngioDynamics (ANGO) points to a 50.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Reasons to Add AngioDynamics Stock to Your Portfolio for Now
ANGO gains momentum as NanoKnife adoption, strong Med Tech growth and positive clinical trends support its long-term outlook.
Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 64.23%: Read This Before Placing a Bet
The mean of analysts' price targets for AngioDynamics (ANGO) points to a 64.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 65.75%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 65.8% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
AngioDynamics CEO Touts Debt-Free Turnaround, Auryon Share Gains, NanoKnife Launch at Needham Conf
AngioDynamics (NASDAQ:ANGO) CEO Jim Clemmer used a presentation at Needham & Company’s 25th Annual Needham Healthcare Conference to outline the company’s multi-year transformation, highlight growth drivers in its MedTech segment, and discuss clinical and commercial plans for its three primary pl